Publication | Closed Access

4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway

4-Hydroxybenzoic AcidBreast OncologyOncologyMedicineHipk2/p53 PathwayBreast CancerAnti-cancer AgentCancer TreatmentPharmacologyCell BiologyCancer ResearchSpecific Hdac6 InhibitorTumor BiologyDrug Discovery